: The U.S. Food and Drug Administration granted full approval to a new Alzheimer’s treatment on July 6, less than three months after President Joe Biden formally announced his candidacy for reelection.

• Leqembi is the first new Alzheimer’s treatment fully approved by the FDA in 20 years, and the first drug that slows progression of the cognitive disease.

• The FDA granted “accelerated approval” for Leqembi in January 2023, roughly three months after Biden attempted to converse with a dead congresswoman at a White House nutrition conference.

• The FDA is a federal agency housed within the Department of Health and Human Services, which is run by a presidential appointee. The timing of the drug’s approval raises some troubling questions about government collusion and election interference.

: This is great news for Biden’s reelection campaign. Leqembi has been shown to “modestly slow the pace of cognitive decline” in Alzheimer’s patients, according to the New York Times.

• A modest reduction may well suffice. Biden, 80, just needs to remain minimally upright and competent until Election Day on Nov. 5, 2024.

• In phase 3 clinical trials, patients taking Leqembi experienced a 27 percent slower rate of decline compared with the placebo group.

• Side effects include brain swelling, seizures, and death.

: Biden reportedly has been prone to violent temper tantrums since taking office, which is a common symptom of Alzheimer’s and other forms of cognitive decline.

• Biden’s cognitive decline was likely exacerbated by his failure to properly treat his longstanding sleep apnea, the Washington Free Beacon reported in June.

: Biden should be resting comfortably at home, surrounded by friends and family. Not running for reelection.

The post COLLUSION? FDA Approves New Alzheimer’s Drug Just in Time for Biden Reelection Campaign appeared first on Washington Free Beacon.